The announcement of Pfizer’s newly developed vaccine trial success rate may allow the public to be more accepting of getting the vaccine, director of the National Institute of Allergy and Infectious Diseases (NIAID) said.
Pfizer recently announced that the vaccine it had developed had a 90 percent efficacy rate for its trial in a press release on Nov. 9.